Molecular profiling reveals potential targets in cholangiocarcinoma

doi:10.3748/wjg.v29.i25.4053

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 25

This Article

(169)

(171)

(0)

(16)

(5368)

(4)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jul 7, 2023; 29(25): 4053-4071
Published online Jul 7, 2023. doi: 10.3748/wjg.v29.i25.4053

Full Size Figure Download Figure

Figure 8 The summary of dysregulated cell cycle and Notch pathways in cholangiocarcinoma progression. The cholangiocarcinogenesis driven by aberrant cell cycle and Notch pathways, which may be targeted by small molecular inhibitors.

Citation: Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK. Molecular profiling reveals potential targets in cholangiocarcinoma. World J Gastroenterol 2023; 29(25): 4053-4071
URL: https://www.wjgnet.com/1007-9327/full/v29/i25/4053.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i25.4053

Liu D, Shi Y, Chen H, Nisar MA, Jabara N, Langwinski N, Mattson S, Nagaoka K, Bai X, Lu S, Huang CK. Molecular profiling reveals potential targets in cholangiocarcinoma. World J Gastroenterol 2023; 29(25): 4053-4071 [PMID: 37476584 DOI: 10.3748/wjg.v29.i25.4053]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.